1-9 of 9
Olivier Mir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis

Nicolas Penel, Sylvie Bonvalot, André-Michel Bimbai, Alexandra Meurgey, François Le Loarer, Sébastien Salas, Sophie Piperno-Neumann, Christine Chevreau, Pascaline Boudou-Rouquette, Pascale Dubray-Longeras, Jean-Emmanuel Kurtz, Cécile Guillemet, Emmanuelle Bompas, Antoine Italiano, Axel Le Cesne, Daniel Orbach, Julien Thery, Marie-Cécile Le Deley, Jean-Yves Blay, Olivier Mir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 4105–4111.
https://doi.org/10.1158/1078-0432.CCR-21-4235
Published: 15 September 2022
View article titled, Lack of Prognostic Value of <em>CTNNB<sub>1</sub></em> Mutation Profile in Desmoid-Type Fibromatosis
Open the PDF for Lack of Prognostic Value of <em>CTNNB<sub>1</sub></em> Mutation Profile in Desmoid-Type Fibromatosis in another window
Includes: Supplementary data
Journal Articles

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Bruno Vincenzi, Andrea Napolitano, Marta Fiocco, Olivier Mir, Piotr Rutkowski, Jean-Yves Blay, Peter Reichardt, Heikki Joensuu, Elena Fumagalli, Spyridon Gennatas, Nadia Hindi, Margherita Nannini, Mariella Spalato Ceruso, Antoine Italiano, Giovanni Grignani, Antonella Brunello, Silvia Gasperoni, Tommaso De Pas, Giuseppe Badalamenti, Maria A. Pantaleo, Winan J. van Houdt, Nikki S. IJzerman, Neeltje Steeghs, Hans Gelderblom, Ingrid M.E. Desar, Johanna Falkenhorst, Marianna Silletta, Marta Sbaraglia, Giuseppe Tonini, Javier Martin-Broto, Peter Hohenberger, Axel Le Cesne, Robin L. Jones, Angelo P. Dei Tos, Alessandro Gronchi, Sebastian Bauer, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1672–1679.
https://doi.org/10.1158/1078-0432.CCR-21-1665
Published: 14 April 2022
View article titled, Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Open the PDF for Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study in another window
Includes: Supplementary data
Journal Articles

Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response

Olivier Mir, Charles Honoré, Ali N. Chamseddine, Matthieu Faron, Leila Haddag-Miliani, Arnaud Bayle, Axel Le Cesne
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 2120.
https://doi.org/10.1158/1078-0432.CCR-21-0041
Published: 01 April 2021
View article titled, Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response
Open the PDF for Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis—Response in another window
Journal Articles

Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of CTNNB1 Mutational Status

Olivier Mir, Charles Honoré, Ali N. Chamseddine, Julien Dômont, Sarah N. Dumont, Andrea Cavalcanti, Matthieu Faron, Françoise Rimareix, Leila Haddag-Miliani, Cécile Le Péchoux, Antonin Levy, Charles Court, Sylvain Briand, Elie Fadel, Olaf Mercier, Arnaud Bayle, Anaïs Brunet, Carine Ngo, Etienne Rouleau, Julien Adam, Axel Le Cesne
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (23): 6277–6283.
https://doi.org/10.1158/1078-0432.CCR-20-1847
Published: 01 December 2020
View article titled, Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <em>CTNNB1</em> Mutational Status
Open the PDF for Long-term Outcomes of Oral Vinorelbine in Advanced, Progressive Desmoid Fibromatosis and Influence of <em>CTNNB1</em> Mutational Status in another window
Includes: Supplementary data
Journal Articles

Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)

Roberta Sanfilippo, Robin L. Jones, Jean-Yves Blay, Axel Le Cesne, Salvatore Provenzano, Georgios Antoniou, Olivier Mir, Giovanni Fucà, Elena Fumagalli, Rossella Bertulli, Silvia Stacchiotti, Mehdi Brahmi, Federica Grosso, Armelle Dufresne, Nadia Hindi, Marta Sbaraglia, Alessandro Gronchi, Paola Collini, Angelo P. Dei Tos, Paolo G. Casali
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5295–5300.
https://doi.org/10.1158/1078-0432.CCR-19-0288
Published: 03 September 2019
View article titled, Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
Open the PDF for Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas) in another window
Includes: Supplementary data
Journal Articles

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, François Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, François Le Loarer, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4859.
https://doi.org/10.1158/1078-0432.CCR-19-1599
Published: 01 August 2019
View article titled, Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Open the PDF for Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study in another window
Journal Articles

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

Maud Toulmonde, Jean-Yves Blay, Olivier Bouche, Olivier Mir, Nicolas Penel, Nicolas Isambert, Florence Duffaud, Emmanuelle Bompas, Thomas Esnaud, Romain Boidot, Damien Geneste, François Ghiringhelli, Carlo Lucchesi, Carine A. Bellera, François Le Loarer, Antoine Italiano
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4611–4615.
https://doi.org/10.1158/1078-0432.CCR-18-3127
Published: 01 August 2019
View article titled, Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study
Open the PDF for Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study in another window
Includes: Supplementary data
Journal Articles

Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials

Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean-Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. Van Erp, Hans Gelderblom, Winette T. Van der Graaf, Alessandro Gronchi
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (5): 1479–1485.
https://doi.org/10.1158/1078-0432.CCR-18-2748
Published: 01 March 2019
View article titled, Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Open the PDF for Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials in another window
Includes: Supplementary data
Journal Articles

Individualized Pazopanib Dosing—Letter

Olivier Mir, Sophie Broutin, Audrey Perret, Axel Le Cesne, Angelo Paci
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6298.
https://doi.org/10.1158/1078-0432.CCR-16-2104
Published: 15 December 2016
View article titled, Individualized Pazopanib Dosing—Letter
Open the PDF for Individualized Pazopanib Dosing—Letter in another window